ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Small molecule SMU-CX24 targeting toll-like receptor 3 counteracts inflammation: A novel approach to atherosclerosis therapy

Cen, Xiaohong; Wang, Baoqu; Liang, Yuqing; Chen, Yanlin; Xiao, Yu; Du, Shaohua; Nandakumar, Kutty Selva; Yin, Hang*; Liu, Shuwen*; Cheng, Kui*南方医科大学; 清华大学
Acta Pharmaceutica Sinica B2022-9DOI: 10.1016/j.apsb.2022.06.001
5被引10阅读
引用收藏
分享

摘要

Toll-like receptor 3 (TLR3), as an important pattern recognition receptor (PRR), dominates the innate and adaptive immunity regulating many acute and chronic inflammatory diseases. Atherosclerosis is proved as an inflammatory disease, and inflammatory events involved in the entire process of initiation and deterioration. However, the contribution of TLR3 to atherosclerosis remains unclear. Herein, we identified the clinical relevance of TLR3 upregulation and disease processes in human atherosclerosis. Besides, activation of TLR3 also directly led to significant expression of atherogenic chemokines and adhesion molecules. Conversely, silencing TLR3 inhibited the uptake of oxLDL by macrophages and significantly reduced foam cell formation. Given the aberrance in TLR3 functions on atherosclerosis progression, we hypothesized that TLR3 could serve as novel target for clinical atherosclerosis therapy. Therefore, we developed the novel ellipticine derivative SMU-CX24, which specifically inhibited TLR3 (IC50 = 18.87 perpendicular to 2.21 nmol/L). In vivo, atherosclerotic burden was alleviated inWestern diet fed ApoE(-/-) mice in response to SMU-CX24 treatment, accompanying notable reductions in TLR3 expression and inflammation infiltration within atherosclerotic lesion. Thus, for the first time, we revealed that pharmacological downregulation of TLR3 with specific inhibitor regenerated inflammatory environment to counteract atherosclerosis progression, thereby proposing a new strategy and probe for atherosclerosis therapy.

学科与关键词

关键词
Toll-like receptor 3AtherosclerosisSmall moleculeInflammationMacrophage
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
Acta Pharmaceutica Sinica B
发表日期
2022-09
卷期
第 12 卷, 第 9 期
页码
3667-3681
DOI
10.1016/j.apsb.2022.06.001
期刊收录
CSCD-C.CAST-L
期刊等级
1区
成果收录
SCIE
资助标注
National Natural Science Foundation of China [81773558, 82073689, 1825702]; National Natural Science Foundation of Guangdong Province [2020A151501518, 2018B030312010]; Science and Technology Program of Guangzhou [201904010380]

作者

  • C

    Cen, Xiaohong (第一作者)

    new · southern med univ

  • W

    Wang, Baoqu

    new · southern med univ

查看全部 10 位作者收起作者
  • L

    Liang, Yuqing

    new · southern med univ

  • C

    Chen, Yanlin

    new · southern med univ

  • X

    Xiao, Yu

    new · southern med univ

  • D

    Du, Shaohua

    southern med univ

  • N

    Nandakumar, Kutty Selva

    new · southern med univ

  • Y

    Yin, Hang (通讯)

    tsinghua univ

  • L

    Liu, Shuwen (通讯)

    new · southern med univ

  • C

    Cheng, Kui (通讯)

    new · southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417